leadf
logo-loader
viewANGLE PLC

Angle expects "deluge of news" in months ahead as Parsortix makes progress

Andrew Newland, chief executive officer at Angle PLC (LON:AGL), tells Proactive Investors the latest interim release marks six months of "consistent progress" against the company's strategy.

He says he hopes Angle will be the first company authorised by the FDA to commercialise liquid biopsy systems and expects "a deluge" of news to come through in the months ahead.

Quick facts: ANGLE PLC

Price: 48.5 GBX

AIM:AGL
Market: AIM
Market Cap: £83.81 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of ANGLE PLC named herein, including the promotion by the Company of ANGLE PLC in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Angle’s Newland reflects on excellent year as cancer patient trials advance

Angle Plc (LON:AGL, OTCMKTS:ANPCY) is poised to revolutionise cancer treatment with its Parsortix system, here we catch up with chief executive Andrew Newland. As Newland explains Parsortix can capture cancer cells from blood, which is very significant for the emerging field of...

on 07/28/2016

2 min read